Substance Use Disorder (SUD) Education: DEA Requirement

• ACP Pain Management 7: Opioid Use Disorder 5 CME
  This interactive training module provides background information necessary to support clinicians in their care for persons with opioid use disorder (OUD), including persons with coexisting chronic pain.
• Alcohol Use Conversations Tool
  Developed in collaboration with the American Society of Addiction Medicine, this AI-powered simulation tool enables clinicians to practice motivational interviewing techniques in brief conversations with virtual patients presenting with risky alcohol behaviors in a safe, non-judgmental environment followed by immediate, individualized feedback.

• Alcohol Use and Chronic Health Conditions Mini Video Series 
  ACP’s new five-video interactive series helps physicians strengthen practical skills for identifying and addressing unhealthy alcohol use in clinical care. Designed for practicing physicians in internal medicine, primary care, family medicine, hospital medicine, and related fields, this member-exclusive resource emphasizes concise, evidence-based strategies that can be applied in everyday practice. 
• X-Express: The ABCs of Prescribing Buprenorphine 1 CME
  This highly practical one-hour video course provides an overview of the role buprenorphine plays in the management of opioid use disorder.

• Treatment for Alcohol Use Disorder: 5 Pearls Segment
  This Core IM 5 Pearls podcast episode on AUD treatment gives internal medicine physicians the tools to confidently offer naltrexone and troubleshoot when it “doesn’t work,” and to know when to reach for acamprosate, topiramate, gabapentin, or other options.
• High-Concentration Cannabinoids: Are They Safe? 1 CME
  In this episode of Annals On Call, Dr. Centor discusses currently available evidence about high-concentration cannabis products and mental health outcomes with Drs. Paula Riggs and Jonathan Samet.
• Alcohol: Is Any Amount Safe for Health? 1 CME
  Should any amount of alcohol be considered safe for health? What about evidence showing associations between modest alcohol consumption and reduced risk for cardiometabolic disease?
• Kratom: A Substance Physicians Should Be Aware Of 1 CME
  In this episode of Annals On Call, Dr. Centor discusses kratom and what physicians should know about how patients may be using this substance with Drs. Eileen Barrett and Amanda Collar.

• Xylazine Adulteration of the Heroin–Fentanyl Drug Supply, A Narrative Review 0.5 CME
  Clinical experience along with the available pertinent research were used to review Xylazine, an animal sedative, and provide guidance on the care of patients exposed to Xylazine, published in Annals of Internal Medicine. After reading the article, follow instructions on the Point-of-Care CME page to claim credit.

• ACP-AMA Naloxone Guidance - ACP has partnered with the AMA to prevent opioid-related overdoses by improving access to naloxone. This joint fact sheet reviews indications for naloxone prescription and addresses other considerations when prescribing naloxone.

Beginning on June 27th, 2023, the DEA will require one-time attestation (checking a box on the online registration form) of training on management of substance use disorders (SUDs) prior to renewal of a DEA registration. The DEA has released guidance on the new one-time requirement for completion of eight hours of training on the treatment and management of patients with opioid or other SUDs.

Yes! As an ACCME-accredited (with commendation) organization, ACP’s offerings qualify on the basis of the stipulation stating that “any other organization accredited by the Accreditation Council for Continuing Medical Education (AACCME)…directly or through an organization accredited by a State medical society that is recognized by the ACCME…”

Yes. Past training on the treatment and management of patients with SUD via ACP can count towards meeting the requirement even if prior to the enactment of this new training obligation. Additionally, the training does not have to occur in one session. It can be cumulative across multiple sessions that equal eight hours of training.

The attestation will only be solicited by the DEA upon registration (new or renewal) after the implementation date of June 27th, 2023. So, if you renewed your license in January of 2023, you would not be required to attest to your participation in training until the time of your next renewal.

Yes. Past DATA-Waived trainings count towards a DEA registrant’s 8-hour training requirement. Section 1262 of the Consolidated Appropriations Act, 2023 (also known as Omnibus bill), removes the federal requirement for practitioners to submit a Notice of Intent (have a waiver) to prescribe medications, like buprenorphine, for the treatment of opioid use disorder (OUD). The education requirement refers to substance use disorders and not exclusively opioid use disorder; therefore the 8 hours can be completed cumulatively in a variety of areas comprising SUD and across multiple sessions that total 8 hours of training.

The DEA currently accepts attestation of recent training only if you graduated from an accredited US medical school (MD or DO) within 5 years of June 27, 2023. During your school years you must have successfully completed a comprehensive curriculum that included at least eight hours of training on managing opioid or other SUDs, including use of all drugs approved by the FDA for SUD treatment. International medical graduates and graduates of US medical schools without comprehensive SUD curriculum should complete accredited CME content, even if CME hours are not formally submitted, to meet the attestation obligations.

According to the DEA FAQs page, If you never plan on administering, dispensing or prescribing a controlled substance in your practice, you are not required to hold a DEA registration. ACP recommends you review the FAQ page of the DEA website for more information.